Amgen (AMGN) Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
Tweet Send to a FriendGet Alerts AMGN Hot Sheet
Price: $105.63 --0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 1.7%
EPS Growth %: +21.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 1.7%
EPS Growth %: +21.7%
Trade AMGN Now!
Amgen (Nasdaq: AMGN) Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amgen To Present At The UBS Global Life Sciences Conference
- New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer
- Medtronic (MDT) Receives CE Mark for Export Advance Catheter
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
